8-K: Lifeward Reports Q2 Loss Amid Strategic Shifts

Lifeward Ltd. announced its second quarter 2025 financial results, reporting a wider net loss due to a goodwill impairment charge, despite operational efficiencies and key strategic advancements.

Summary

• Revenue for the second quarter of 2025 was $5.7 million, a 15% decrease from $6.7 million in Q2 2024, but a 14% increase from $5.0 million in Q1 2025.
• GAAP net loss widened to $6.6 million, or $0.58 per share, in Q2 2025, compared to $4.3 million, or $0.50 per share, in Q2 2024, primarily due to a $2.8 million goodwill impairment charge.
• Non-GAAP net loss improved slightly to $3.5 million, or $0.31 per share, in Q2 2025, from $3.6 million, or $0.42 per share, in Q2 2024.
• Cash used in operations improved to $3.9 million in Q2 2025, down from $5.6 million in Q2 2024 and $5.5 million in Q1 2025, driven by operational efficiencies and facility consolidations.
• The company achieved FDA clearance and launched the ReWalk 7 in April 2025, with over 20 units installed.
• Lifeward recorded the highest quarterly total of ReWalk units placed for Medicare beneficiaries since the fee schedule was established in April 2024.
• A ruling by an Administrative Law Judge affirmed the medical necessity of the ReWalk Personal Exoskeleton for Medicare beneficiaries.
• The company successfully transitioned to in-house manufacturing of the ReWalk Personal Exoskeleton during Q2, concluding its agreement with Sanmina, leading to cost savings and improved quality control.
• Mark Grant was appointed President and CEO, and Almog Adar was appointed CFO to bolster strategic initiatives.

Sentiment

Score: 6

Explanation: While GAAP financial results show a significant net loss increase due to a goodwill impairment and a year-over-year revenue decline, the company demonstrated strong operational improvements, including reduced cash burn, successful transition to in-house manufacturing, and key regulatory and market access achievements for its products. The new management team has also reset guidance, indicating a focus on future execution.

Positives

• Improved quarterly cash burn to $3.9 million, down from $5.6 million in Q2 2024 and $5.5 million in Q1 2025, reflecting operational efficiencies and cost reductions.
• Achieved FDA clearance and U.S. launch of the ReWalk 7 in April 2025, with over 20 units installed and positive customer feedback.
• Recorded the highest quarterly total of ReWalk units placed for Medicare beneficiaries since the fee schedule was established in April 2024.
• Expanded U.S. payer base for the ReWalk Personal Exoskeleton, including a favorable Administrative Law Judge ruling for Medicare medical necessity and the first paid workers' compensation claim via CorLife partnership.
• Successfully transitioned to in-house manufacturing of the ReWalk Personal Exoskeleton, expected to deliver cost savings, improved quality control, and greater production flexibility.
• Non-GAAP net loss improved to $3.5 million in Q2 2025 from $3.6 million in Q2 2024, and non-GAAP operating expenses decreased by $0.9 million year-over-year due to efficiency measures.

Negatives

• Revenue decreased by 15% year-over-year to $5.7 million in Q2 2025 from $6.7 million in Q2 2024.
• GAAP net loss widened significantly to $6.6 million in Q2 2025 from $4.3 million in Q2 2024.
• Total operating expenses increased to $9.1 million in Q2 2025 from $7.2 million in Q2 2024, primarily due to a $2.8 million goodwill impairment charge.
• Goodwill decreased from $7.538 million at December 31, 2024, to $4.755 million at June 30, 2025, reflecting the impairment charge.
• Revenue from AlterG products decreased by 11% year-over-year to $3.2 million, primarily due to the timing of deliveries to international distributors.

Risks

• Uncertainties regarding the acceptance of the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients.
• Risks associated with future clinical trials, product development, and the FDA regulatory submission review and approval process.
• The company's ability to secure sufficient funds to meet future capital requirements, which could impair product development and commercialization efforts.
• Challenges in maintaining and growing the company's reputation and market acceptance of its products.
• Difficulties in achieving reimbursement from third-party payors, including CMS, for its products.
• The company's limited operating history and its ability to effectively leverage its sales, marketing, and training infrastructure.
• Uncertainties regarding the company's clinical research program and the realization of expected clinical results.
• Risks related to future growth, including the ability to increase sales in existing geographic markets and expand to new markets.
• The company's ability to continue to operate as a going concern.
• Challenges in obtaining certain components of its products from third-party suppliers and maintaining continued access to product manufacturers.
• Potential difficulties associated with moving production of AlterG Anti-Gravity Systems to a contract manufacturer and transitioning ReWalk product manufacturing to in-house facilities.
• The company's ability to improve existing products and develop new ones.
• Compliance with medical device reporting regulations for adverse events, which could lead to corrective actions or enforcement actions like mandatory recalls.
• The ability to gain and maintain regulatory approvals.
• Challenges in maintaining adequate protection of intellectual property and avoiding infringement of others' intellectual property rights.
• The risk of a cybersecurity attack or breach of the company's IT systems significantly disrupting business operations.
• The company's ability to effectively use the proceeds from its offerings of securities.

Future Outlook

Lifeward is resetting its full-year 2025 guidance, now expecting revenue between $24 million and $26 million, and a non-GAAP net loss between $12 million and $14 million. The company anticipates continued positive trends in efficiency measures for the second half of 2025.

Management Comments

• "During the second quarter of 2025, we advanced on multiple fronts; improving cash burn through disciplined cost control, securing regulatory and legal milestones that expand market access, strengthening our manufacturing capabilities, and broadening our global reach through strategic partnerships."
• "These achievements position Lifeward for greater efficiency, scale, and impact in delivering innovative mobility solutions worldwide."

Industry Context

Lifeward operates in the innovative medical technology sector, specifically focusing on physical rehabilitation and recovery solutions like exoskeletons and anti-gravity systems. The company's advancements, such as FDA clearance for ReWalk 7 and expanded Medicare coverage, reflect a broader industry trend towards integrating advanced robotics and technology into rehabilitation, aiming to improve patient outcomes and expand market access through favorable reimbursement policies. The focus on in-house manufacturing also aligns with a desire for greater control over supply chains and cost efficiencies in the medical device industry.

Comparison to Industry Standards

• NA

Management Changes

Legal Proceedings

• A ruling by an Administrative Law Judge established a legal basis for medical necessity by affirming that the ReWalk Personal Exoskeleton is reasonable and necessary for a Medicare beneficiary.

Stakeholder Impact

• Shareholders: Impacted by the goodwill impairment charge leading to a wider GAAP net loss and a decline in share price, but potentially benefit from improved operational efficiencies and strategic growth initiatives.
• Customers (patients): Benefit from the FDA clearance and launch of the ReWalk 7, expanded Medicare coverage, and improved manufacturing quality of ReWalk systems.
• Employees: Affected by facility consolidations and cost reduction initiatives, but potentially benefit from strengthened executive leadership and a focus on sustainable growth.
• Suppliers: The transition to in-house manufacturing for ReWalk products concludes the agreement with Sanmina, impacting that specific supplier, while other suppliers for components remain crucial.

Next Steps

• Host a conference call on August 14, 2025, at 8:30 a.m. E.D.T. to discuss financial results.
• Continue efficiency measures in the second half of 2025 to maintain positive trends in operating expenses.
• Execute towards full-year 2025 revenue guidance of $24-$26 million and non-GAAP net loss of $12-$14 million.

Key Dates

Recommendation

The company presents a mixed financial picture with a significant goodwill impairment leading to a wider GAAP net loss and a year-over-year revenue decline. However, strong operational improvements, including reduced cash burn and successful in-house manufacturing transition, alongside key regulatory and market access achievements (FDA ReWalk 7, Medicare ruling), indicate positive strategic momentum. The new management team's reset guidance suggests a focus on future execution. Given the ongoing strategic shifts and the need to observe the impact of these changes on future financial performance, a 'hold' recommendation is appropriate for a seasoned investor.

Keywords

Exoskeleton, Medical Technology, Rehabilitation, Physical Therapy, FDA Clearance, Medicare Reimbursement, Wearable Robotics, Assistive Devices, Mobility Solutions, ReWalk, AlterG, MyoCycle, ReStore, Biomedical Devices